|Articles|October 1, 2012

Retrospective: CleanRooms_Dixon

To view a PDF of this article from the BioPharm International archives, click this link

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content

Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays

ByFeliza Mirasol

January 12th 2026

Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina

ByNicholas Jacbous

January 12th 2026

Transforming Cell Therapy with Precise Human Biology Replication (Part 2)

ByFeliza Mirasol

January 12th 2026

Why AI-Native Cell Manufacturing Is the Future of Drug Discovery (Part 1)

ByFeliza Mirasol

January 9th 2026

Genetically engineered chimeric antigen receptor immune cell with implanted mrna gene strand - 3d illustration | Image Credit: ©Christoph Burgstedt -stock.adobe.com

What Are the Benefits of Single-Use in CGT Manufacturing?

ByCynthia A. Challener

January 7th 2026

Retrospective: CleanRooms_Dixon

Newsletter

Related Content

Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays

Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina

Transforming Cell Therapy with Precise Human Biology Replication (Part 2)

Why AI-Native Cell Manufacturing Is the Future of Drug Discovery (Part 1)

What Are the Benefits of Single-Use in CGT Manufacturing?

Trending on BioPharm International

Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina

Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays

Generative AI and Adaptive Trials Shape Future Biotech Development

Executive Summary: From Molecule to Formulation: A Systematic Approach to Assess Biologics Developability